Next Article in Journal
Gold Nanoparticles for Diagnostics: Advances towards Points of Care
Previous Article in Journal
Gingival Crevicular Fluid as a Novel Potential Source of Biomarkers Distinguishes Pubertal from Post-Pubertal Subjects
Previous Article in Special Issue
The Role of PET/CT Molecular Imaging in the Diagnosis of Recurrence and Surveillance of Patients Treated for Non-Small Cell Lung Cancer
 
 
Review

Targeted Molecular Imaging in Adrenal Disease—An Emerging Role for Metomidate PET-CT

1
Department of Radiology, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Addenbrooke’s Hospital, Cambridge CB2 0QQ, UK
2
Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Addenbrooke’s Hospital, Cambridge CB2 0QQ, UK
3
Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 1TN, UK
4
Department of Radiology, University of Cambridge School of Clinical Medicine, Addenbrooke’s Hospital, Cambridge CB2 0QQ, UK
5
Department of Nuclear Medicine, Cambridge University Hospitals, Cambridge CB2 0QQ, UK
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Andreas J. Kjaer
Diagnostics 2016, 6(4), 42; https://doi.org/10.3390/diagnostics6040042
Received: 24 August 2016 / Revised: 8 November 2016 / Accepted: 9 November 2016 / Published: 18 November 2016
(This article belongs to the Special Issue Positron Emission Tomography (PET) in Cardiology and Oncology)
Adrenal lesions present a significant diagnostic burden for both radiologists and endocrinologists, especially with the increasing number of adrenal ‘incidentalomas’ detected on modern computed tomography (CT) or magnetic resonance imaging (MRI). A key objective is the reliable distinction of benign disease from either primary adrenal malignancy (e.g., adrenocortical carcinoma or malignant forms of pheochromocytoma/paraganglioma (PPGL)) or metastases (e.g., bronchial, renal). Benign lesions may still be associated with adverse sequelae through autonomous hormone hypersecretion (e.g., primary aldosteronism, Cushing’s syndrome, phaeochromocytoma). Here, identifying a causative lesion, or lateralising the disease to a single adrenal gland, is key to effective management, as unilateral adrenalectomy may offer the potential for curing conditions that are typically associated with significant excess morbidity and mortality. This review considers the evolving role of positron emission tomography (PET) imaging in addressing the limitations of traditional cross-sectional imaging and adjunctive techniques, such as venous sampling, in the management of adrenal disorders. We review the development of targeted molecular imaging to the adrenocortical enzymes CYP11B1 and CYP11B2 with different radiolabeled metomidate compounds. Particular consideration is given to iodo-metomidate PET tracers for the diagnosis and management of adrenocortical carcinoma, and the increasingly recognized utility of 11C-metomidate PET-CT in primary aldosteronism. View Full-Text
Keywords: metomidate; nuclear medicine; adrenal; primary aldosteronism; adrenocortical carcinoma metomidate; nuclear medicine; adrenal; primary aldosteronism; adrenocortical carcinoma
Show Figures

Graphical abstract

MDPI and ACS Style

Mendichovszky, I.A.; Powlson, A.S.; Manavaki, R.; Aigbirhio, F.I.; Cheow, H.; Buscombe, J.R.; Gurnell, M.; Gilbert, F.J. Targeted Molecular Imaging in Adrenal Disease—An Emerging Role for Metomidate PET-CT. Diagnostics 2016, 6, 42. https://doi.org/10.3390/diagnostics6040042

AMA Style

Mendichovszky IA, Powlson AS, Manavaki R, Aigbirhio FI, Cheow H, Buscombe JR, Gurnell M, Gilbert FJ. Targeted Molecular Imaging in Adrenal Disease—An Emerging Role for Metomidate PET-CT. Diagnostics. 2016; 6(4):42. https://doi.org/10.3390/diagnostics6040042

Chicago/Turabian Style

Mendichovszky, Iosif A., Andrew S. Powlson, Roido Manavaki, Franklin I. Aigbirhio, Heok Cheow, John R. Buscombe, Mark Gurnell, and Fiona J. Gilbert. 2016. "Targeted Molecular Imaging in Adrenal Disease—An Emerging Role for Metomidate PET-CT" Diagnostics 6, no. 4: 42. https://doi.org/10.3390/diagnostics6040042

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop